Secukinumab re‐initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis
A. Blauvelt; K. Reich; R.B. Warren; J.C. Szepietowski; B. Sigurgeirsson; S. K. Tyring; I. Messina; V. Bhosekar; J. Oliver; C. Papavassilis; J. Frueh; R.G.B. Langley
Author Information: Oregon Medical Research Center
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.